Proteobiotics as a new antimicrobial therapy

Brianna Tarsillo; Ronny Priefer

doi:10.1016/j.micpath.2020.104093

Proteobiotics as a new antimicrobial therapy

Microb Pathog. 2020 Feb 25:142:104093. doi: 10.1016/j.micpath.2020.104093. Online ahead of print.

Authors

Brianna Tarsillo¹, Ronny Priefer²

Affiliations

¹ Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA.
² Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA. Electronic address: ronny.priefer@mcphs.edu.

PMID: 32109571
DOI: 10.1016/j.micpath.2020.104093

Abstract

Antibiotic resistance is a major concern for healthcare. The emergence of resistant bacteria has contributed to an increase in cost, morbidity, and mortality rates of patients. There is evidence to suggest that the inhibition of bacteria's virulence strategies would downregulate their pathogenesis and stop infections while also preventing more resistance. This concept became the backbone of many studies in the arena of human microbiome. Through probiotic studies, novel compounds were discovered that possessed antimicrobial activity. These have become labeled as proteobiotics, i.e. metabolites from probiotics. Proteobiotics have demonstrated the ability to interrupt bacteria cell-to-cell communication. Currently, there is one approved product containing proteobiotic technologies for swine showing positive outcomes.

Keywords: Antibiotic resistance; Pathogenesis; Proteobiotics; Virulence.

Publication types

Review